The FDA issued an alert about decreased survival associated with the use of pembrolizumab (Keytruda, Merck) or atezolizumab (Tecentriq, Genentech) as monotherapy in previously untreated patients with metastatic urothelial cancer and low programmed death ligand-1 expression.